Abstract
Treatment algorithms of Crohn’s disease (CD) and ulcerative colitis (UC) share a lot of similarities. However, despite a variety of common therapeutic pathways, there are a few differences between both diseases that require different treatment approaches. There is no standardized definition on conventional therapy in IBD. In the following chapter steroids and mesalamine are defined as conventional therapy in IBD. The gold standard in the treatment of mild to moderate active ulcerative colitis is mesalamine. Mesalamine also plays an important role in maintenance treatment of UC. Topical application should always be considered as with topical application, much higher concentration of mesalamine could be obtained within the mucosa compared to the oral application. Mesalamine is less frequently used in patients with Crohn’s disease. Budesonide is used as standard treatment for mild to moderate Crohn’s disease with ileocecal involvement. Budesonide MMX exerts a continuous release within the whole colon and can be used in UC patients refractory to mesalamine. Conventional steroids are the method of choice in severe UC and CD. Long term steroid use should be avoided in patients with IBD. Mesalamine and steroids have no role in maintenance therapy of CD. If maintenance therapy appears to be useful in CD patients, immunosuppressive drugs or biologicals should be used. In the following chapter, we will present a therapeutic algorithm on how to use conventional drugs in patients with ulcerative colitis and Crohn’s disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Andus T, Kocjan A, Muser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD et al (2010) Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 16(11):1947–1956
Barnes PJ (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol 163(1):29–43
Becker DE (2013) Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog 60(1):25–31; quiz 2
Benchimol EI, Seow CH, Steinhart AH, Griffiths AM (2008) Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev (2):CD006792. https://doi.org/10.1002/14651858.CD006792.pub2
Cohen RD, Woseth DM, Thisted RA, Hanauer SB (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95(5):1263–1276
Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC (2009) Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev (4):CD006873. https://doi.org/10.1002/14651858.CD006873.pub2
Duricova D, Pedersen N, Elkjaer M, Jensen JK, Munkholm P (2010) 5-aminosalicylic acid dependency in Crohn’s disease: a Danish Crohn Colitis Database study. J Crohns Colitis 4(5):575–581
Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK et al (2011) Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 106(4):617–629
Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 11(7):769–784
Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53(11):1617–1623
Lim WC, Wang Y, MacDonald JK, Hanauer S (2016) Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 7:CD008870
Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ (2010) Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (1):CD004115. https://doi.org/10.1002/14651858.CD004115.pub2
Nielsen OH, Munck LK (2007) Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4(3):160–170
Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J et al (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92(10):1867–1871
Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH (2008) Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev (3):CD000296. https://doi.org/10.1002/14651858.CD000296.pub3
Travis SP, Danese S, Kupcinskas L, Alexeeva O, D’Haens G, Gibson PR et al (2014) Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 63(3):433–441
Tromm A, Bunganic I, Tomsova E, Tulassay Z, Lukas M, Kykal J et al (2011) Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 140(2):425–434.e1; quiz e13–4
Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK (2016a) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543
Wang Y, Parker CE, Feagan BG, MacDonald JK (2016b) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (5):CD000544. https://doi.org/10.1002/14651858.CD000544.pub4
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kucharzik, T., Asthana, A.K. (2019). Medical Management 2: Conventional. In: Sturm, A., White, L. (eds) Inflammatory Bowel Disease Nursing Manual. Springer, Cham. https://doi.org/10.1007/978-3-319-75022-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-75022-4_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-75021-7
Online ISBN: 978-3-319-75022-4
eBook Packages: MedicineMedicine (R0)